Hemophilia A Gene Therapy Durable at 2 Years; Under FDA Review Hemophilia A Gene Therapy Durable at 2 Years; Under FDA Review

Despite an anticipated price tag of $2.5 million, there ' s no way to predict who will have long-standing benefit from valoctocogene roxaparvovec and who will not.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news